Investors & Media

Investors & Media

Welcome to our investor page

We aspire to individualize cancer medicine

BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. To translate this idea into reality, we have combined ground-breaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and beyond. As we prove the value of our approach in the clinic, we will continue to build the partnerships, manufacturing and team required to bring individualized treatments to patients worldwide. From our roots in Mainz, Germany, we are driven to become the leading global biotechnology company for individualized cancer medicine.

 

Stock Quote

Aug 3, 2020 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Upcoming Events

August 11, 2020

Second Quarter 2020 update

August 13, 2020 at 2:00 PM EDT

Canaccord Genuity 40th Annual Growth Conference

November 10, 2020

Third Quarter 2020 update

Upcoming events (more)

Press Releases

31 July 2020

Pfizer and BioNTech to Supply Japan with 120 Million Doses of Their BNT162 mRNA..

31 July 2020

BioNTech Announces Strategic Collaboration with Regeneron to Advance FixVac and..

30 July 2020

BioNTech Publishes Data from mRNA-based BNT111 FixVac Melanoma Trial in Nature

Press releases (more)